Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	11.63	3.09	11.25	14.55	19.99
Cash & Short-Term Investments	11.63	3.09	11.25	14.55	19.99
Cash Growth	275.80%	-72.49%	-22.69%	-27.21%	560.69%
Other Receivables	0.07	-	-	-	-
Receivables	0.07	-	-	-	-
Prepaid Expenses	0.26	0.41	0.42	1.03	1.67
Total Current Assets	11.96	3.51	11.67	15.58	21.65
Other Long-Term Assets	0.18	0.57	-	-	-
Total Assets	12.15	4.07	11.67	15.58	21.65
Accounts Payable	0.22	0.16	0.53	0.38	0.11
Accrued Expenses	0.26	0.1	0.53	0.13	0.13
Total Current Liabilities	0.49	0.26	1.07	0.51	0.24
Total Liabilities	0.49	0.26	1.07	0.51	0.24
Common Stock	0.04	0.03	0.03	0.02	0.02
Additional Paid-In Capital	85.51	69.19	67.78	60.51	60.03
Retained Earnings	-73.89	-65.4	-57.2	-45.47	-38.64
Total Common Equity	11.66	3.81	10.6	15.07	21.41
Shareholders' Equity	11.66	3.81	10.6	15.07	21.41
Total Liabilities & Equity	12.15	4.07	11.67	15.58	21.65
Net Cash (Debt)	11.63	3.09	11.25	14.55	19.99
Net Cash Growth	275.80%	-72.49%	-22.69%	-27.21%	607.78%
Net Cash Per Share	0.34	0.12	0.45	0.62	1.47
Filing Date Shares Outstanding	41.08	25.93	25.63	23.37	23.34
Total Common Shares Outstanding	41.08	25.93	25.63	23.34	23.34
Working Capital	11.47	3.25	10.6	15.07	21.41
Book Value Per Share	0.28	0.15	0.41	0.65	0.92
Tangible Book Value	11.66	3.81	10.6	15.07	21.41
Tangible Book Value Per Share	0.28	0.15	0.41	0.65	0.92

Updated Sep 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q